Clinical trials: Iron
Beta-Thalassemia
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
This study is a Phase 2 multicenter, randomized, open-label, parallel-group study. The primary objective of the study is to evaluate the effect of LJPC-401 (synthetic human hepcidin) on iron levels in patients with…
- Trial name
- NCT03381833
- Testing
- LJPC-401
- Where
- 22 sites in United States, Australia and 6 more
- Volunteers
- 84 people
- Sponsor
- La Jolla Pharmaceutical Company
β-thalassemia, Transfusional Iron Overload
Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
The primary purpose of this study is to evaluate the effect of deferasirox on renal hemodynamics by determining glomerular filtration rate (GFR), renal plasma flow (RPF) and filtration fraction (FF).
- Trial name
- NCT00560820
- Testing
- Deferasirox
- Where
- 3 sites in Italy
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Patients With Chemotherapy Induced Anemia (CIA)
Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia
The purpose of this study is to assess Pharmakokinetic properties of iron isomaltoside 1000 (Monofer®) in doses of 250 mg and 500 mg in patients suffering from Chemotherapy Induced anemia.
- Trial name
- PK-CIA-06 (NCT01280240)
- Testing
- Monofer(R)
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Pharmacosmos A/S
Chronic Kidney Disease
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
The current registry is being undertaken to assess the long-term (12 month) safety and tolerability of Venofer in the pediatric population with chronic kidney disease that requires intravenous iron maintenance therapy.
- Trial name
- NCT02492672
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- American Regent, Inc.
Anemia, Chronic Kidney Disease
Safety and Efficacy of Iron Sucrose in Children
Comparison of three potential iron sucrose maintenance regimens in pediatric chronic kidney disease (CKD) patients
- Trial name
- NCT00239642
- Testing
- Venofer (iron sucrose injection)
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- American Regent, Inc.
Iron Deficiency Anemia
Iron Indices and Intravenous Ferumoxytol: Time to Steady State
The purpose of this study is to evaluate the time point of transferrin saturation (TSAT) and ferritin stabilization after a thirteen-treatment period following a ferumoxytol load, as well as to determine the point at which serum…
- Trial name
- NCT01148745
- Testing
- ferumoxytol
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dialysis Clinic, Inc.
Inflammatory Bowel Disease
Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia
The purpose of the trial is to demonstrate that intravenous iron oligosaccharide is non-inferior to oral iron sulphate in reducing iron deficiency anaemia secondary to inflammatory bowel disease (IBD), evaluated as the ability to…
- Trial name
- NCT01017614
- Testing
- Monofer, Iron Sulphate
- Where
- 10 sites in Denmark, India and 1 more
- Volunteers
- 350 people
- Sponsor
- Pharmacosmos A/S
Beta-thalassemia, Iron Overload
Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
The purpose of this trial is to evaluate changes in cardiac iron as measured by MRI T2* in beta-thalassemia patients with deferasirox treatment.
- Trial name
- NCT00447694
- Testing
- Deferasirox
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Novartis
Transfusional Iron Overload, Beta-thalassemia
Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload
The purpose of this research study is to evaluate the safety of two doses of FBS0701, a new oral iron chelator, and its effectiveness in clearing iron from the liver.
- Trial name
- NCT01186419
- Testing
- SPD602 (FBS0701, SSP-004184)
- Where
- 9 sites in United States, Italy and 3 more
- Volunteers
- 51 people
- Sponsor
- Shire
Anemia
Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia
The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent
- Trial name
- NCT00704353
- Testing
- Ferric Carboxymaltose, Standard Medical Care (SMC)
- Where
- United States
- Volunteers
- 735 people
- Sponsor
- American Regent, Inc.
Acute Kidney Injury
Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent
This trial will evaluate whether treatment with CRMD001 (unique formulations of the iron chelator, Deferiprone) will reduce morbidity and mortality in subjects with Chronic Kidney Disease (CKD) and additional risk factors.
- Trial name
- NCT01391520
- Testing
- deferiprone
- Sponsor
- CorMedix Therapeutics
Iron Deficiency, Anaemia
Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia
An Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Ferric Carboxymaltose (FCM) in Infants (0-1 year) with Iron Deficiency Anemia.
- Trial name
- NCT04968379
- Testing
- Ferric carboxymaltose
- Where
- 4 sites in United States
- Sponsor
- American Regent, Inc.
Kidney Failure, Chronic, Anemia, Iron-Deficiency
Effect of Two Iron Preparations on Protein in the Urine
This pilot study will compare the effects of sodium ferric gluconate complex and iron sucrose on urine concentrations of various chemicals including protein
- Trial name
- NCT00354692
- Testing
- Sodium Ferric Gluconate and Iron sucrose
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Watson Pharmaceuticals
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)
MOMENTUM is a randomized, double-blind, active control Phase 3 trial intended to confirm the differentiated clinical benefits of the investigational drug momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic…
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- NCT04173494
- Testing
- Momelotinib, Danazol
- Where
- 167 sites in United States, Australia and 20 more
- Volunteers
- 195 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Anemia, Iron-Deficiency, Inflammatory Bowel Disease
Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD
The purpose of this study is to compare the efficacy of ferric maltol and intravenous iron (IVI) Ferric Carboxy Maltose in the treatment of iron deficiency anaemia (IDA) and subsequent maintenance of haemoglobin in subjects with…
- Conditions
- Anemia, Iron-Deficiency, Inflammatory Bowel Disease, Crohn's Disease
- Trial name
- NCT02680756
- Testing
- Ferric Maltol, Ferric Carboxy Maltose
- Where
- 44 sites in United States, Belgium and 4 more
- Volunteers
- 250 people
- Sponsor
- Shield Therapeutics
Hereditary Hemochromatosis
PTG-300 in Subjects With Hereditary Hemochromatosis
This study will be conducted at multiple sites and every patient will get treated with PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult hereditary hemochromatosis patients.
- Trial name
- NCT04202965
- Testing
- PTG-300
- Where
- 11 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Protagonist Therapeutics, Inc.
Thalassemia Major
Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation
This study is a multicenter, open-label, two-period crossover design that evaluates the safety, tolerability, pharmacokinetics and preliminary evidence of iron chelating activity of DST-0509 as compared to Jadenu and Exjade in…
- Trial name
- NCT03637556
- Testing
- DST-0509, Jadenu, Exjade
- Where
- 4 sites in United States, Thailand
- Volunteers
- 25 people
- Sponsor
- DisperSol Technologies, LLC
Iron Deficiency, Fibromyalgia
Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia
This study investigates the efficacy and safety of an IV iron Injectafer in the treatment of iron deficient patients with fibromyalgia.
- Trial name
- NCT02409459
- Testing
- Injectafer
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- American Regent, Inc.
Kidney Failure, Chronic, Anemia, Iron-Deficiency
Comparison Between Effects of Two Iron Preparations on Protein in the Urine
This study will compare the effects of sodium ferric gluconate complex and iron sucrose on urine concentrations of various chemicals including protein
- Trial name
- NCT00534144
- Testing
- iron sucrose injection, USP, sodium ferric gluconate complex in sucrose injection
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 74 people
- Sponsor
- Watson Pharmaceuticals
Iron Overload
Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients
The primary objective is to assess the safety of Ferriprox oral solution for the treatment of iron overload in pediatric patients with transfusion-dependent anemia.
- Trial name
- NCT00529152
- Testing
- Deferiprone
- Where
- 4 sites in Egypt, Indonesia and 1 more
- Volunteers
- 100 people
- Sponsor
- ApoPharma